Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECAN: Apixaban Coagulation Activity in NVAF
NCT03136510Terminated
- Sponsor
- Hôpital Lariboisière
- Start
- Sep 2016
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of apixaban in Atrial fibrillation (AFib) (2 arms), sponsored by Hôpital Lariboisière. Primary endpoint: Change in D-dimers level at 3 months. Started Sep 2016; status: terminated.
02
Drugs
apixaban
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT03136510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03136510.